M&T Bank Corp trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 30.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 37,762 shares of the life sciences company's stock after selling 16,616 shares during the quarter. M&T Bank Corp's holdings in Illumina were worth $5,046,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of the business. Janney Montgomery Scott LLC lifted its holdings in shares of Illumina by 73.3% in the third quarter. Janney Montgomery Scott LLC now owns 6,580 shares of the life sciences company's stock valued at $858,000 after purchasing an additional 2,783 shares in the last quarter. QRG Capital Management Inc. lifted its stake in Illumina by 21.7% in the 3rd quarter. QRG Capital Management Inc. now owns 8,411 shares of the life sciences company's stock valued at $1,097,000 after acquiring an additional 1,502 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new position in Illumina during the 3rd quarter worth approximately $209,000. Portside Wealth Group LLC grew its stake in shares of Illumina by 13.2% during the 3rd quarter. Portside Wealth Group LLC now owns 2,276 shares of the life sciences company's stock worth $297,000 after acquiring an additional 265 shares in the last quarter. Finally, AIA Group Ltd raised its holdings in shares of Illumina by 13.1% in the third quarter. AIA Group Ltd now owns 65,214 shares of the life sciences company's stock valued at $8,505,000 after purchasing an additional 7,547 shares during the last quarter. 89.42% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on the stock. Royal Bank of Canada decreased their target price on shares of Illumina from $250.00 to $247.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Guggenheim decreased their price objective on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday. Barclays downgraded Illumina from an "equal weight" rating to an "underweight" rating and decreased their price target for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Finally, HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and an average target price of $149.25.
Check Out Our Latest Analysis on ILMN
Shares of NASDAQ ILMN traded up $1.97 during trading hours on Friday, reaching $86.62. 3,237,038 shares of the stock were exchanged, compared to its average volume of 2,651,085. The firm has a market capitalization of $13.72 billion, a price-to-earnings ratio of -11.28, a P/E/G ratio of 1.60 and a beta of 1.17. The stock's fifty day simple moving average is $118.38 and its 200 day simple moving average is $131.50. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.